

This week in therapeutics

| Indication | Target/marker/pathway | Summary | Licensing status | Publication and contact information |
|---------------|---|--|---|---|
| Cancer | | | | |
| Cancer | Signal regulatory protein- α (SIRPA); CD47 | <p>Studies in cell culture suggest inhibiting interactions between SIRPA and CD47 could improve the efficacy of therapeutic mAbs. In a breast cancer cell line, combining Herceptin trastuzumab with an anti-SIRPA antibody increased cell killing compared with Herceptin alone. Next steps include developing additional SIRPA-targeting antibodies.</p> <p>Roche's Genentech Inc. unit markets Herceptin, an anti-HER2 (EGFR2; ERBB2; neu) antibody, to treat breast and gastric cancers.</p> <p>SciBX 4(44); doi:10.1038/scibx.2011.1230 Published online Nov. 10, 2011</p> | Patent application filed; available for licensing | <p>Zhao, X.W. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Oct. 31, 2011; doi:10.1073/pnas.1106550108</p> <p>Contact: Timo K. van den Berg, University of Amsterdam, Amsterdam, the Netherlands e-mail: t.k.vandenberg@sanquin.nl</p> |